Finally, genetic variations such as Single Nucleotide Polymorphisms (SNPs) in the MDM2 promoter (e.g., SNP309T>G) can disrupt the coordinated p53-MDM2 oscillation by increasing MDM2 expression, further influencing cancer susceptibility and the efficacy of therapeutic interventions [12,13]. The gene discussed is TP53; the disease is cancer.